Advances in clinical chemistry. Volume 84 /

• Άλλοι συγγραφείς: Makowski, Gregory S. (Gregory Stephen)
• Μορφή: Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Cambridge, MA : Academic Press, 2018.
• Σειρά: Advances in Clinical Chemistry Volume 84
• Θέματα: Clinical chemistry.; HEALTH & FITNESS > Diseases > General.; MEDICAL > Clinical Medicine.; MEDICAL > Diseases.; MEDICAL > Evidence-Based Medicine.; MEDICAL > Internal Medicine.; Electronic books.

Πίνακας περιεχομένων:

• Front Cover; Advances in Clinical Chemistry; Copyright; Contents; Contributors; Preface; Chapter One: Protein Carbamylation: Chemistry, Pathophysiological Involvement, and Biomarkers; 1. Introduction; 2. The Carbamylation Reaction; 3. Impact of Carbamylation on Protein Properties; 3.1. Alteration of Structural Properties; 3.2. Loss of Function; 3.3. Impairment of Protein-Protein and Protein-Cell Interactions; 4. Protein Carbamylation in Aging and Diseases; 4.1. Aging; 4.2. Cataract; 4.3. Chronic Kidney Disease; 4.4. Atherosclerosis; 4.5. Rheumatoid Arthritis; 4.6. Neurological Disorders.
• 5. Biomarkers of Protein Carbamylation5.1. Carbamylated Hemoglobin; 5.2. Carbamylated LDLs; 5.3. Free Carbamylated Amino Acids; 5.4. Carbamylated Albumin; 5.5. Homocitrulline; 6. Analytical Methods for the Measurement of CDPs; 6.1. Colorimetric Assay; 6.2. Immunoassay; 6.3. Chromatographic Methods; 6.4. HPLC-MS/MS; 6.5. Capillary Electrophoresis; 7. Conclusion; Conflict of Interest; References; Chapter Two: Inflammatory Response During Myocardial Infarction; 1. Introduction; 2. Inflammatory Phase; 2.1. Danger-Associated Molecular Patterns; 2.1.1. High-Mobility Group Box 1 Protein.
• 2.1.2. Extracellular ATP2.1.3. Mitochondrial DNA; 2.1.4. Heat-Shock Proteins; 2.1.5. Fibronectin; 2.1.6. Calgranulins S100; 2.1.7. Extracellular RNA; 2.2. Pattern Recognition Receptors; 2.2.1. Toll-Like Receptors; 2.2.2. Receptor for Advanced Glycation End Product; 2.2.3. NOD-Like Receptors; 2.3. The Nuclear Factor Kappa B; 2.4. The Complement System; 2.5. Reactive Oxygen Species; 2.6. Cytokines; 2.6.1. TNF-É#x91;; 2.6.2. IL-1; 2.6.3. IL-6; 2.7. Chemokines; 2.8. Cellular Effectors; 2.8.1. Neutrophils; 2.8.2. Monocytes/Macrophages; 2.8.3. Cardiac Fibroblasts; 2.8.4. DCs and Lymphocytes.
• 3. Proliferative Phase3.1. Inflammation Suppression; 3.1.1. Cellular Effectors; 3.1.2. Molecular Signaling; 3.2. Scar Formation and Fibrosis; 3.2.1. Fibroblast Spread and Transdifferentiation; 3.2.2. Extracellular Matrix Rearrangement; 4. Maturation Phase; 5. Cardiac Remodeling; 5.1. Early Cardiac Remodeling; 5.2. Late Cardiac Remodeling; 6. MI and Atherosclerosis: A Dual Path; 7. Conclusion; References; Chapter Three: Metabolomics of Major Depressive Disorder and Bipolar Disorder: Overview and Future Perspective; 1. Introduction; 2. MDD; 2.1. Blood Samples.
• 2.2. Blood Biomarkers of Ketamine's Antidepressant Actions in Patients With MDD2.3. Urine Samples; 2.4. Cerebrospinal Fluid (CSF) Samples; 3. BD; 3.1. Postmortem Brain Samples; 3.2. Blood Samples; 3.3. Blood Biomarkers for Ketamine's Antidepressant Actions in Patients With BD; 3.4. Urine Samples; 3.5. CSF Samples; 4. Conclusion and Future Direction; Acknowledgment; Conflict of Interest; References; Chapter Four: Blood Glucose Determination: Effect of Tube Additives; 1. Introduction; 2. Literature Search; 3. Search Results; 3.1. Impact of Citrate Buffer on Glucose Concentration and Stability.